


IN THE CLAIMS

The status of the claims is listed below.

Claim 1 (Currently Amended): A compound of the formula (I):



wherein R^1 is hydrogen or lower alkyl;
 R^2 is lower alkyl optionally substituted with halogen, hydroxy, lower alkoxyimino or lower alkoxy; lower alkenyl; cycloalkyl; cyano; lower alkanoyl; cycloalkylcarbonyl; N,N-di(lower)alkylcarbamoyl; carbamoyl; N-lower alkoxy-N-lower alkylcarbamoyl; amino; di(lower)alkylamino; lower alkoxy carbonylamino; N,N-di(lower)alkylcarbamoylamino; N-(N,N-di(lower)alkylcarbamoyl)-N-lower alkylamino; halogen; hydroxy; carboxy; lower alkoxy carbonyl; aroyl; heterocyclic carbonyl; heterocyclic group; lower alkylsulfonyl; lower alkoxy optionally substituted with lower alkoxy, N,N-di(lower)alkylcarbamoyl or halogen; cycloalkyloxy; lower alkylthio; or lower alkylsufinyl;
 R^3 is lower alkyl optionally substituted with amino, carbamoylamino or lower alkylsulfonylamino; halogen; cyano; hydroxy; lower alkanoyloxy; lower alkylene dioxy; lower alkoxy optionally substituted with aryl, hydroxy,

cyano, amino, lower alkoxycarbonylamino, lower alkylsulfonylamino or carbamoylamino; nitro; amino; ~~heterocyclic group~~; lower alkylthio; lower alkylsulfinyl; or lower alkylsufonyl;

R^4 is ~~hydrogen, cyano, amino optionally substituted with phthaloyl or lower alkyl, aryl, heterocyclic group, lower alkoxy, hydroxy, lower alkylsulfonyloxy, lower alkanoyloxy, lower alkyl substituted with tritylamo~~ and ~~lower alkoxy carbonyl, amino and lower alkoxy carbonyl, amino and carboxy, amino and carbamoyl, or amino and hydroxy, N lower alkoxycarbonyl N lower alkylamino, lower alkanoyl optionally substituted with halogen, carboxy, lower alkylsulfonyl, sulfo, lower alkylsilyloxy, lower alkoxycarbonyl, sulfamoyl optionally substituted with lower alkyl, carbamoyl optionally substituted with lower alkyl, lower alkylthio, lower alkylsulfinyl, carbamoyloxy, thioureido, or~~
a group of the formula:

R^5 -G- J-

in which G is $-CO-$ or $-SO_2-$;

J is $-N(R^6)-$

(wherein R^6 is hydrogen or lower alkyl); and

R^5 is amino optionally substituted with lower alkoxycarbonyl or lower alkyl; lower alkyl optionally substituted with hydroxy, lower alkoxycarbonylamino, lower alkanoyloxy, amino or halogen; lower alkoxy; hydrogen; ~~heterocyclic group~~; or aryl;

X is O, S, SO or SO_2 ;

Y is CH or N;

Z is lower alkylene or lower alkenylene; and

m is 0 or 1;

~~provided that when R⁴ is hydrogen;~~

~~then R³ is lower alkyl substituted with amino, carbamoylamino or lower alkylsulfonylamino; or lower alkoxy substituted with aryl, hydroxy, cyano, amino, lower alkoxy carbonylamino, lower alkylsulfonylamino or carbamoylamino;~~

or a salt thereof.

Claim 2 (Currently Amended): The compound of Claim 1, wherein

R¹ is hydrogen;

R² is lower alkyl optionally substituted with halogen, hydroxy, lower alkoxyimino or lower alkoxy; cycloalkyl; halogen; lower alkoxy optionally substituted with halogen; or lower alkylthio;

R³ is lower alkoxy optionally substituted with aryl, hydroxy, cyano, amino, lower alkoxy carbonylamino, lower alkylsulfonylamino or carbamoylamino;

~~R⁴ is a group of the formula:~~

R⁵-G-J

~~in which R⁵, G and J are each as defined in claim 1;~~

X is O or S; and

Z is lower alkylene.

Claim 3 (Currently Amended): The compound of Claim 2, wherein

R² is lower alkyl optionally substituted with halogen; cycloalkyl; halogen; or lower alkoxy optionally substituted with halogen;

R³ is lower alkoxy;

~~R⁴ is a group of the formula:~~

~~R⁵-G-J~~

~~in which G is -CO- or -SO₂-,~~

~~J is -NH- and~~

~~R⁵ is amino or lower alkyl; and~~

~~X is O.~~

Claim 4 (Original): The compound of Claim 3, which is

N-(2-(4-[3-chloro-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]-phenoxy)ethyl)urea,

N-(4-[3-(difluoromethyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-

yl]benzyl)methanesulfonamide,

N-(4-[3-(difluoromethyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]benzyl)urea,

N-(2-(4-[3-(difluoromethyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-

yl]phenoxy)ethyl)urea,

N-(2-(4-[1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-

yl]phenoxy)ethyl)urea,

N-(2-(4-[3-(difluoromethyl)-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-

yl]phenoxy)ethyl)urea,

N-(2-(4-[3-cyclopropyl-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy)ethyl)urea,

N-(2-(4-[3-(difluoromethyl)-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-

yl]phenoxy)ethyl)urea,

N-(2-(4-[1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-

yl]phenoxyethyl)acetamide, or

N-(2-(4-[3-(2,2-difluoroethoxy)-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-

yl]phenoxy)ethyl)urea.

Claim 5: (Canceled).

Claim 6 (Original): A pharmaceutical composition comprising the compound of Claim 1, as an active ingredient, in association with a pharmaceutically non-toxic carrier or excipient.

Claim 7: (Canceled).


Claim 8 (Currently Amended): A method for treatment ~~and/or prevention~~ of inflammatory conditions, ~~pain various pains~~, collagen diseases, autoimmune diseases, ~~various~~ immunity diseases, analgesic, thrombosis, cancer or neurodegerative diseases which comprises administering an effective amount of the compound of Claim 1 to a human beings or an animals.

Claims 9-12: (Canceled).


Claim 13 (New): A method of treating an inflammatory condition, comprising administering an effective amount of the compound of Claim 1 to a human being or an animal.

Claim 14 (New): A process of preparing a compound of Claim 1 or a salt thereof, comprising:


1) reacting a compound of the formula:



or a salt thereof with a compound of the formula:




or a salt thereof in the acidic condition to provide a compound of the formula:



or a salt thereof, in the above formulas,

or


2) reacting a compound of the formula:



or a salt thereof with a compound (V) of the formula:



or a salt thereof to provide a compound of the formula:



or a salt thereof,

wherein R¹, R², R³, R⁴, X, Y, Z and m are each as defined in Claim 1,

Xa is O or S, and

Q is hydroxy or an acid residue.

SUPPORT FOR THE AMENDMENTS

The amendments to the pending claims and newly-added Claims 13-14 are supported by the specification. Accordingly, no new matter is believed to have been added to the present application by the amendments submitted above.